TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01504009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle training
Description: 12 weeks of strength training 2-3 times/week
Study: NCT04039555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 intimate
Description: Two sessions with CO2 intimate laser for vaginal symptoms treatment

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium-yag
Description: Two sessions with Erbium-yag laser for vaginal symptoms treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CO2 intimate or Erbium-yag
Description: Two sessions of one of the two lasers with no therapeuthical energy
Study: NCT00961896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Placebo cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225 0.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDE225 0.75%
Study: NCT02591706

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIS Implants
Description: The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIS Implants
Description: The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
Study: NCT04085705

Intervention type: DIAGNOSTIC_TEST
Intervention: PATCH test
Description: The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
Study: NCT03632226

Intervention type: DRUG
Intervention: 18F-OGA-1
Study: NCT00908427

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: photoselective vaporization prostatectomy (PVP)
Description: PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
Study: NCT02738957

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Prenatal Counseling Group
Description: Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models.
Study: NCT04047771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
Study: NCT01436968

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aglatimagene besadenovec + valacyclovir
Description: Patients will receive three courses of ProstAtak® each consisting of aglatimagene besadenovec injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + valacyclovir
Description: Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~1. The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~2. The second injection will be 0-3 days before initiation of radiation therapy.~3. The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
Study: NCT02503982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prophylactic Valganciclovir
Description: The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
Study: NCT01585818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) intervention arm
Description: The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet Intervention
Description: The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
Study: NCT02514577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-122 Lotion
Description: Topical lotion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP-122 Vehicle Lotion
Description: Topical lotion. No active ingredient.
Study: NCT03209245

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Purethal Mites
Description: perennial allergren specific immunotherapy during 24 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: perrenial injection wich were administered in same protocol as Purethal

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: monitoring of allergen specific IgE
Description: measurement the serum specific IgE at the start and at the end of trial

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: monitoring of allergen specific IgE
Description: measurement the serum specific IgE at the start and at the end of trial

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: monitoring of allergen specific IgG4
Description: measurement the serum specific IgG4 at the start and at the end of trial

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: monitoring of allergen specific IgG4
Description: measurement the serum specific IgG4 at the start and at the end of trial
Study: NCT05140707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: The patients were administered to use the virtual reality device and they were free to choose the theme and video in the library to watch. Patients used the device during the port catheter implantation and untill the 4 hour after the implantation when they felt pain.
Study: NCT01015378

Intervention type: PROCEDURE
Intervention: laparoscopid sigmoid resection
Description: A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
Study: NCT00908427

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: Standard transurethral resection of the prostate using electrocautery loop
Study: NCT02314754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol 24-48 hours later
Description: 200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
Study: NCT01964339

Intervention type: OTHER
Intervention: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.
Description: Venous blood gas, basic metabolic panel, PSG variable data collection.

Intervention type: OTHER
Intervention: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.
Description: Arterial blood gas, basic metabolic panel, PSG variable data collection
Study: NCT02684955

Intervention type: DEVICE
Intervention: Cerebral spectroscopy
Description: Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.

Intervention type: DEVICE
Intervention: Pupillometry
Description: The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
Study: NCT03184597

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HLA screening before commencing aromatic AEDs
Description: When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HLA screening before commencing aromatic AEDs
Description: When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HLA screening before commencing aromatic AEDs
Description: When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HLA screening before commencing aromatic AEDs
Description: When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
Study: NCT02622256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health System: HTN Intervention
Description: Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team \& may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
Study: NCT02517528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-333
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Tablet
Study: NCT02986750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo Eye Drops
Description: Manufacturer: Laboratoires Thea, France

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optive Eye Drops
Description: Manufacturer: Allergan Pharmaceuticals, Ireland

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systane Ultra Eye Drops
Description: Manufacturer: Alcon Pharma GmbH
Study: NCT04315129

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Smart Catheter Biosensor
Description: A novel biosensor in-built into the catheter drainage system that monitors the chemical composition of the urine, with the intention of providing early diagnosis of developing infection
Study: NCT03087994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional guidance intervention
Description: participants in this group will attend 12 meeting of nutritional guidance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional guidance intervention
Description: Participants in this group will only receive nutrition guidance once during the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional guidance intervention
Description: Participants in this group will only receive nutrition guidance once during the study
Study: NCT02097849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tetanus diphtheria toxoids vaccine
Description: Administered as described in the treatment arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus diphtheria toxoids vaccine
Description: Administered as described in the treatment arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Administered as described in the treatment arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: Administered as described in the treatment arm

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)
Description: Administered as described in the treatment arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)
Description: Administered as described in the treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-pegylated interferon
Description: Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
Study: NCT02845310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restricted fluid therapy group
Description: Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV \< 10% - MAP \>65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP \> 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (\>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard fluid management
Description: Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
Study: NCT01911923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No CPAP/PEEP and 100 % oxygen
Description: This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP/PEEP and 30 % oxygen
Description: During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
Study: NCT04240600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: 2 cans or bottles (200ml)per day, orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: 2 cans or bottles (200ml)per day, orally
Study: NCT01572298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft alone
Description: use of MinerOss allograft plus Alloderm GBR membrane and tenting screws

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: allograft with autograft
Description: use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
Study: NCT01542398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention
Description: A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
Study: NCT03015597

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of \<10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
Study: NCT00443898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle (placebo) applied once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle (placebo) applied once daily for 24 weeks
Study: NCT00002644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate 20Mg Tab
Description: Tamoxifen Citrate 20Mg Tab

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20Mg Tab
Study: NCT03161886

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pan-enteric Capsule Endoscopy (PCE)
Description: Second generation of colon capsule endoscopy (Medtronic)